Annual report
2413.TEDINET S100W3NK
Period2024-04-01 → 2025-03-31
Filed2025-06-25
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 157
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥284.9bn | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥238.9bn | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥230.8bn | 2022-04-01 → 2023-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥208.2bn | 2021-04-01 → 2022-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥169.2bn | 2020-04-01 → 2021-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥63.0bn | 2024-04-01 → 2025-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥64.4bn | 2023-04-01 → 2024-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥64.8bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥68.8bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥74.3bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥96.2bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥58.3bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥40.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥45.3bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥49.0bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥63.8bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥37.8bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥44.3bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥48.5bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥581.7bn | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥490.8bn | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥400.6bn | at 2023-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥346.0bn | at 2022-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥273.1bn | at 2021-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥168.9bn | at 2025-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥124.1bn | at 2024-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥412.8bn | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥366.7bn | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥309.5bn | at 2023-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥378.4bn | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥351.9bn | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥302.6bn | at 2023-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥257.8bn | at 2022-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥199.8bn | at 2021-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥134.9bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥149.7bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥118.3bn | at 2023-03-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥104.3bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥89.1bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥51.7bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥58.3bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥57.1bn | 2022-04-01 → 2023-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥52.1bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥46.6bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥39.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥39.5bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥21.9bn | 2022-04-01 → 2023-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥23.4bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | ¥3.6bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥27.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥9.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥22.8bn | 2022-04-01 → 2023-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥16.4bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥11.6bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥59.62 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥66.68 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥72.22 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥94.06 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥55.73 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥59.6 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥66.63 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥72.17 | 2022-04-01 → 2023-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥93.98 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥55.68 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥555.07 | at 2025-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥516.49 | at 2024-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥444.22 | at 2023-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥378.75 | at 2022-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥293.64 | at 2021-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 65.1% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 71.7% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 75.5% | at 2023-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 74.5% | at 2022-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 73.2% | at 2021-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 11.1% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 13.8% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 17.5% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 27.9% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 20.7% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 15,360 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 12,100 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 10,533 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 9,384 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 8,249 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥45.2bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥51.5bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥54.5bn | 2022-04-01 → 2023-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥55.7bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥49.9bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥19.1bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥23.6bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥27.5bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥84.0bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥28.0bn | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥32.3bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥30.8bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥27.4bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥84.5bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥21.4bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥75.9bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥19.8bn | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥20.5bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥22.0bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥265.1bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥251.2bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥232.6bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥215.4bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥195.4bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥31.9bn | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥25.2bn | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥233.1bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥226.0bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥162.1bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥152.5bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥139.8bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥78.8bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥105.0bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥31.56 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥111.85 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥29.14 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥30.17 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥32.41 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥31.56 | 2024-04-01 → 2025-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥111.77 | 2023-04-01 → 2024-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥29.12 | 2022-04-01 → 2023-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥30.15 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥32.38 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥21 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥21 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥19 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥16 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥12 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥341.34 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥331.17 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥237.22 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥223.54 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥205.3 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 87.4% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.5% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 69.2% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.4% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 71.3% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 9.4% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 39.4% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 12.6% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 14.1% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 16.8% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 679,077,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 679,063,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 678,964,000 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 678,904,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 678,785,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 704 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 649 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 588 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 574 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 554 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 64
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥3.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥3.8bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥3.1bn |
| Career Solutionreportable segment | employees | at 2025-03-31 | 973 pure |
| Career Solutionreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥20.9bn |
| Career Solutionreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥20.9bn |
| Career Solutionreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥32m |
| Career Solutionreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥5.7bn |
| Evidence Solutionreportable segment | employees | at 2025-03-31 | 2359 pure |
| Evidence Solutionreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥24.2bn |
| Evidence Solutionreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥24.0bn |
| Evidence Solutionreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥223m |
| Evidence Solutionreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥4.3bn |
| Medical Platformreportable segment | employees | at 2025-03-31 | 2439 pure |
| Medical Platformreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥91.6bn |
| Medical Platformreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥88.2bn |
| Medical Platformreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥3.4bn |
| Medical Platformreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥34.1bn |
| Overseasreportable segment | employees | at 2025-03-31 | 2995 pure |
| Overseasreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥80.6bn |
| Overseasreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥80.5bn |
| Overseasreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥64m |
| Overseasreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥14.7bn |
| Patient Solutionreportable segment | employees | at 2025-03-31 | 1266 pure |
| Patient Solutionreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥21.9bn |
| Patient Solutionreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥21.9bn |
| Patient Solutionreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥824m |
| Site Solutionreportable segment | employees | at 2025-03-31 | 5145 pure |
| Site Solutionreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥47.0bn |
| Site Solutionreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥47.0bn |
| Site Solutionreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥12m |
| Site Solutionreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥5.4bn |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥286.3bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥282.5bn |
| —segment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥3.7bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥65.1bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥3.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥3.4bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥863m |
| Career Solutionreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥16.6bn |
| Career Solutionreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥16.6bn |
| Career Solutionreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥36m |
| Career Solutionreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥4.8bn |
| Evidence Solutionreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥26.7bn |
| Evidence Solutionreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥26.4bn |
| Evidence Solutionreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥314m |
| Evidence Solutionreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥6.7bn |
| Medical Platformreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥93.4bn |
| Medical Platformreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥90.5bn |
| Medical Platformreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥2.9bn |
| Medical Platformreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥38.6bn |
| Overseasreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥69.9bn |
| Overseasreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥69.9bn |
| Overseasreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥16m |
| Overseasreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥11.7bn |
| Site Solutionreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥33.0bn |
| Site Solutionreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥33.0bn |
| Site Solutionreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥13m |
| Site Solutionreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥3.7bn |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥239.6bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥236.3bn |
| —segment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥3.3bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥65.5bn |
| Medical Platformreportable segment | employees | at 2025-03-31 | 612 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,858
| Item | Context | Value | Unit |
|---|---|---|---|
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)執行役員 大 場 啓 史 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E05425 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 24130 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)エムスリー株式会社 | |
| Filer name in english | FilingDateInstant | M3, Inc. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第三号様式 | |
| Accounting standards | FilingDateInstant | IFRS | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Current fiscal year start date | FilingDateInstant | 2024-04-01 | |
| Current period end date | FilingDateInstant | 2025-03-31 | |
| Type of current period | FilingDateInstant | FY | |
| Current fiscal year end date | FilingDateInstant | 2025-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2023-04-01 | |
| Comparative period end date | FilingDateInstant | 2024-03-31 | |
| Previous fiscal year end date | FilingDateInstant | 2024-03-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Business results of reporting company (text) | FilingDateInstant | Text · Plus | |
| Company history (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Overview of affiliated entities (text) | FilingDateInstant | Text · Plus | |
| Information about employees (text) | FilingDateInstant | Text · Plus | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | Original text (Japanese)エムスリーソリューションズ㈱ | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row2Member | Original text (Japanese)メビックス㈱ | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row3Member | Original text (Japanese)エムスリーキャリア㈱ | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row4Member | Original text (Japanese)エムスリーマーケティング㈱ | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row5Member | Original text (Japanese)ノイエス㈱ | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row6Member | Original text (Japanese)㈱日本アルトマーク | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row7Member | Original text (Japanese)㈱メディサイエンスプラニング | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row8Member | Original text (Japanese)㈱シーユーシー | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row9Member | Original text (Japanese)ソフィアメディ㈱ | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row10Member | Original text (Japanese)㈱シーユーシー・ホスピス | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row11Member | Original text (Japanese)㈱ノアコンツェル | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row12Member | Original text (Japanese)㈱エラン | |
| Business policy business environment issues to address etc (text) | FilingDateInstant | Text · Plus | |
| Disclosure of sustainability related financial information (text) | FilingDateInstant | Text · Plus | |
| Reference to other information | FilingDateInstant | Original text (Japanese)当社HP（https://corporate.m3.com/esg） | |
| Strategy (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |